Pulmonary arterial hypertension trials put to the test: Using the fragility index to assess trials robustness.
In: Heart & Lung, Jg. 61 (2023-09-01), S. 147-152
academicJournal
Zugriff:
• Fragility index analysis reveals low robustness of significant outcomes in PAH RCTs. • Included RCTs had a median FI of 10, indicating fragility of the results. • Moderate correlation was found between FI and sample size or journal impact factor. Randomized clinical trials (RCTs) are considered the gold standard for evidence-based medicine. The Fragility Index (FI) is a tool to assess the robustness of RCT results. FI was validated for dichotomous outcomes and recent work expanded its use to continuous outcomes. Studying the robustness of RCTs in Pulmonary Arterial Hypertension (PAH) treatments is crucial due to the severity and mortality risks associated with this rare condition. Analyze FI and Fragility quotient (FQ) of significant primary outcomes in PAH RCTs and study FI correlation with sample size and journal impact factor. FI and FQ calculation followed by Spearman correlation to assess the correlation between FI and sample size, and FI and impact factor. The median sample size of the 21 trials was 202 patients (IQR 106–267), with 6 trials reporting primary outcomes as dichotomous and 15 reporting continuous primary outcomes. The median FI was 10 (IQR 3–20), and the median FQ was 0.044 (0.026–0.097). A moderate correlation was found between FI and sample size, with r = 0.56; P = 0.008 and FI and journal impact factor (r =0.50; P =0.019). The FI for continuous outcomes was similar to that for dichotomous outcomes. This study represents the first analysis of the FI and FQ of PAH treatment RCTs, and expands the use of FI to continuous outcomes in this context. The moderate correlation between FI and sample size suggests that increasing sample size alone is partially correlated to a higher FI. The similarity between FI for continuous and dichotomous outcomes supports the broader use of FI in PAH RCTs. [ABSTRACT FROM AUTHOR]
Copyright of Heart & Lung is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Pulmonary arterial hypertension trials put to the test: Using the fragility index to assess trials robustness.
|
---|---|
Autor/in / Beteiligte Person: | Garcia, Marcos Vinicius Fernandes ; Coz-Yataco, Angel ; Al-Jaghbeer, Mohammed J. |
Zeitschrift: | Heart & Lung, Jg. 61 (2023-09-01), S. 147-152 |
Veröffentlichung: | 2023 |
Medientyp: | academicJournal |
ISSN: | 0147-9563 (print) |
DOI: | 10.1016/j.hrtlng.2023.05.019 |
Sonstiges: |
|